Ataxia-telangiectasia (A-T) is an autosomal-recessive chromosomal breakage syndrome caused by the mutations of the ATM gene located on chromosome 11q23. A-T manifests in early childhood with progressive cerebellar ataxia and oculocutaneous telangiectases and is associated with an increased risk of lymphoid malignancies, especially non-Hodgkin's lymphoma and T-ALL. The incidence of the disease is estimated at 1 in 100 000 live births. 1 Heterozygous carriers of ATM mutations have an increased risk of all types of cancers. 2 ATM gene targets include P53 and BRCA1, which explains the predisposition of carriers to breast cancer. The chemotherapy tolerance in A-T patients is decreased because of chromosomal instability, but clinical data are scarce. 3, 4 For the first time, we report the long-term survival of a 3-year-old boy with A-T syndrome and T-ALL after allogeneic-matched sibling donor PBSC transplantation.
CASE REPORT
The patient was misdiagnosed at infancy with ataxic cerebral palsy; A-T was confirmed by mutational analysis after a leukaemia diagnosis at the age of 3. Upon presentation, the peripheral blood (PB) count revealed hyperleucocytosis (WBC 66 K/mL) with 67% leukaemic blasts in the PB smear and 71% in the BM. In the flow-cytometric analysis, the blasts were positive for CD5, CD7, CD8, CD10, CD45 and cytoplasmic CD3. The diagnostic karyotyping revealed a complex karyotype with typical del(6q), t(7;14) as well as atypical unbalanced aberrations with three copies of the AML1 gene and deletion of TP53, as highlighted by the following:
45,X,der(Y)t(Y;15),r(1),del(6)(q21q23),der(7)t(7;14)(q35;q11),der(8) t(5;8),der(17)t(1;17)(q21;p13),dup(21)(q21q22)(cp25).
The leukaemia treatment was based on the ALL IC-BFM 2002 protocol, with dosage adjustments made according to the reported BFM experience for patients with A-T and lymphoma. 3 The induction chemotherapy (protocol I) was not modified. Because of poor prednisone response on day 8 of the induction therapy (25 K blastic cells per ml in the PB), the patient was scheduled for high-risk chemotherapy with subsequent allo-SCT. The indication for allo-SCT in patients with T-ALL and poor prednisone response (defined as blast count over 1000 per mL on day 8 of induction therapy) was strictly protocol based. The BM blast percentages were 1.5% and 0.25% on days 15 and 33, respectively, and the minimal residual disease evaluation was not performed. The patient was treated using the modified HR1-HR2-HR3-HR1 protocols ( Table 1) .
The BM donor was the HLA-matched younger brother, in whom A-T was genetically excluded. We modified the German conditioning regimen used in Fanconi anaemia (GEFA02) with i.v. busilvex at 0.5 mg/kg body weight (BW) given twice daily on The chemotherapy-induced toxicities observed after SCT were grade IV leucopenia (0.25 K/mL) with agranulocytosis (0.13 K/mL) and mucositis (grade II). Immunosuppression induced concomitant multiple viral infections, including adenoviraemia, BKV haemorrhagic cystitis and EBV lymphoproliferative disorder (EBV-LPD). These three infections were relatively mild and were successfully treated with cidofovir, which shows anti-replicative activity against all three pathogens, and rituximab, which targets EBV-LPD specifically. The ANC recovery was achieved on day þ 15, with a mixed chimerism (MC) of 33% donor cells. The patient received four DLIs for persistent and increasing autologous chimerism (Figure 1) . The DLIs were administered at 4, 5, 8 and 10 months after the SCT, and the T-cell dose was incrementally increased from 1 Â 10 6 to 50 Â 10 6 CD3 þ cells per kg BW. The patient did not develop any symptoms of either acute or chronic GVHD. The DLIs used whole blood from the donor (DLI1), unmanipulated, unstimulated PB apheresis product (DLI2 and DLI4), or cryopreserved, unstimulated PB apheresis product (DLI3). During observation, the percentage of donor chimerisms in the CD3 þ subpopulation ranged between 94.4 and 98.3%, whereas the percentage of donor chimerisms in both the BM and the PB reached lower values, with an initially decreasing trend that eventually stabilised. Further DLIs and attempts at a second SCT procedure were refused by the patient's parent. Despite MC, the patient remains in complete haematological remission 3.5 years after the SCT with normal blood count values. The transplantation did not worsen the patient's neurological status, and we observed transient neurological improvement during the methylprednisolone therapy, which is a newly reported, and as yet unexplained, phenomenon. 5 
DISCUSSION AND CONCLUSIONS
Until now, no recommendations existed regarding the BMT conditioning regimen in patients with A-T. 6 Only two cases of HSCT in A-T are known. One patient was conditioned with 36 g/m 2 treosulfan and 150 mg/m 2 fludarabine and transplanted from an HLA-matched-related donor died after 8 months due to encephalopathy and hepatic toxicities, but the patient was transplanted for a misdiagnosed immunodeficiency, and the A-T diagnosis was made post-mortem. 7 The second patient was diagnosed with A-T and conditioned with 10 g/m 2 cytarabin and 150 mg/m The GEFA02 protocol was successfully used in our centre in eight patients with Fanconi anaemia and one child with Nijmegen breakage syndrome. 8 The GEFA02 conditioning regimen in the patient with A-T enabled durable engraftment but lacked myeloablative properties. Low haematological toxicities and MC in the transplanted child suggest that A-T patients can be safely conditioned more intensively, which supports the use of the new GEFA03 protocol. This protocol includes treatment with 40 mg/kg CY, as well as alemtuzumab, instead of ATG and OKT-3. The reported case shows that allo-SCT in patients with a malignancy and A-T remains a feasible and promising option. Because A-T patients have a higher susceptibility to cancer, these patients must be followed closely because of the 26% reported incidence risk of second malignancies, with a median latency of 3.5 (range 3.2-10) years. Letter to the Editor
